Finanzen von Barinthus Biotherapeutics PLC (BRNS)BRNSBarinthus Biotherapeutics PLC

In the context of the broader market, BRNS competes directly with industry leaders such as NNVC and ATNM. With a market capitalization of $28.86M, it holds a significant position in the sector. When comparing efficiency, BRNS's gross margin of N/A stands against NNVC's N/A and ATNM's 100.00%. Such benchmarking helps identify whether Barinthus Biotherapeutics PLC is trading at a premium or discount relative to its financial performance.

The company has reported substantial net losses, including -$10.58 million in Q2 2026 and a negative EPS of -0.26. However, it has a strong gross margin of 100% in Q3 2024, but this has not been sustained in recent quarters.